publication date: Feb. 3, 2014
NCI CTEP Approved Trials For the Month of January
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
9524: A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy with Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS. Johns Hopkins University; Gojo, Ivana. (410) 328-2596
9539: A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination with PANVAC(TM) Versus BCG Given Alone in Adults with High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG. National Cancer Institute Urologic Oncology Branch; Agarwal, Piyush K. (301) 496-6353
ACNS1221: A Phase II Study for the Treatment of Non-Metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age. Children’s Oncology Group; Lafay-Cousin, Lucie. (403) 955-2554
ACRIN-6702: A Multi-Center Study Evaluating the Utility of Diffusion Weighted Imaging for Detection and Diagnosis of Breast Cancer. American College of Radiology Imaging Network; Partridge, Savannah Corrina (206) 288-1306
E2212: A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver. Eastern Cooperative Oncology Group; Libutti, Steven Kenneth. (718) 920-4231
S1310: Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer. Southwest Oncology Group; Kim, Richard D. (813) 745-1277
A091105: A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid … Continue reading CCL Jan – NCI CTEP Trials
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.